AP2139A
(en)
|
2004-04-02 |
2010-08-21 |
Osi Pharm Inc |
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
|
EP1906950A4
(en)
*
|
2005-06-21 |
2008-09-24 |
Infinity Discovery Inc |
ANSAMYCIN FORMULATIONS AND METHODS OF USE
|
JP5682051B2
(ja)
*
|
2006-05-18 |
2015-03-11 |
ファーマサイクリックス,インク. |
細胞内キナーゼ阻害剤
|
WO2008021347A2
(en)
*
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Method for making solid dispersions of highly crystalline therapeutic compounds
|
PL2526771T3
(pl)
|
2006-09-22 |
2017-06-30 |
Pharmacyclics Llc |
Inhibitory kinazy tyrozynowej Brutona
|
ES2403546T3
(es)
*
|
2006-11-03 |
2013-05-20 |
Pharmacyclics, Inc. |
Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
|
US20120101114A1
(en)
*
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
AU2008232762B2
(en)
*
|
2007-03-28 |
2013-09-19 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
BRPI0810835A2
(pt)
*
|
2007-04-12 |
2015-06-16 |
Infinity Discovery Inc |
Formulações de hidroquinona ansamicina
|
TWI552752B
(zh)
|
2007-10-19 |
2016-10-11 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
US7989465B2
(en)
*
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
US20110046144A1
(en)
*
|
2008-01-18 |
2011-02-24 |
Mulvihill Mark J |
Imidazopyrazinol derivatives for the treatment of cancers
|
WO2009143051A1
(en)
*
|
2008-05-19 |
2009-11-26 |
Osi Pharmaceuticals, Inc. |
Substituted imidazopyr-and imidazotri-azines
|
US20090301928A1
(en)
*
|
2008-06-05 |
2009-12-10 |
United Comb & Novelty Corporation |
Packaging For Lipped Containers
|
MX357627B
(es)
|
2008-06-27 |
2018-07-17 |
Avila Therapeutics Inc |
Compuestos de heteroarilo y usos de los mismos.
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
WO2010006947A1
(en)
|
2008-07-15 |
2010-01-21 |
F. Hoffmann-La Roche Ag |
Novel phenyl-imidazopyridines and pyridazines
|
EP2307025B1
(en)
*
|
2008-07-16 |
2017-09-20 |
Pharmacyclics LLC |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
AU2013245503B2
(en)
*
|
2008-07-16 |
2015-09-24 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
|
US20100185419A1
(en)
*
|
2008-09-05 |
2010-07-22 |
Avila Therapeutics, Inc. |
Algorithm for designing irreversible inhibitors
|
KR20110090925A
(ko)
*
|
2008-10-15 |
2011-08-10 |
인피니티 파마슈티컬스, 인코포레이티드 |
안사마이신 하이드로퀴논 조성물
|
WO2010043633A1
(en)
*
|
2008-10-15 |
2010-04-22 |
Palau Pharma, S. A. |
2h-pyrazolo [4,3-d]pyrimidin-5-amine derivatives as h4 histamine receptor antagonists for the treatment of allergic, immunological and inflammatory diseases
|
US9095592B2
(en)
*
|
2008-11-07 |
2015-08-04 |
The Research Foundation For The State University Of New York |
Bruton's tyrosine kinase as anti-cancer drug target
|
US8426428B2
(en)
*
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
JP2012524119A
(ja)
|
2009-04-20 |
2012-10-11 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
C−ピラジン−メチルアミンの調製
|
WO2010126960A1
(en)
|
2009-04-29 |
2010-11-04 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
JP5918693B2
(ja)
|
2009-05-05 |
2016-05-18 |
ダナ ファーバー キャンサー インスティテュート インコーポレイテッド |
Egfr阻害剤及び疾患の治療方法
|
JP2012526138A
(ja)
*
|
2009-05-07 |
2012-10-25 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
副腎皮質癌を治療するためのosi−906の使用
|
EP3461824B1
(en)
|
2009-09-04 |
2021-08-25 |
Biogen MA Inc. |
Bruton's tyrosine kinase inhibitors
|
KR20120104521A
(ko)
*
|
2009-09-11 |
2012-09-21 |
사일린 파마슈티칼스, 인크 |
약제학적으로 유용한 헤테로사이클-치환된 락탐
|
BR112012005962A8
(pt)
|
2009-09-16 |
2018-01-02 |
Avila Therapeutics Inc |
Conjugados de proteína quinase, compostos e composição farmacêutica compreendendo os referidos compostos
|
US7965498B2
(en)
|
2009-09-30 |
2011-06-21 |
Apple Inc. |
Cover glass to housing interface system
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
RU2012132473A
(ru)
|
2009-12-30 |
2014-02-10 |
Селджин Авиломикс,Инк |
Лиганд-направленная ковалентная модификация белка
|
US20130149346A1
(en)
*
|
2010-03-08 |
2013-06-13 |
ratiopharm GmbH Graf-Arco-Strasse 3 |
Dabigatran etexilate-containing pharmaceutical composition
|
US9371567B2
(en)
*
|
2010-04-19 |
2016-06-21 |
The Translational Genomics Research Institute |
Methods and kits to predict therapeutic outcome of BTK inhibitors
|
ES2782873T3
(es)
|
2010-05-31 |
2020-09-16 |
Ono Pharmaceutical Co |
Derivado de purinona como inhibidor de Btk quinasa
|
EA201890869A3
(ru)
|
2010-06-03 |
2019-03-29 |
Фармасайкликс, Инк. |
Применение ингибиторов тирозинкиназы брутона (btk)
|
US20120053189A1
(en)
*
|
2010-06-28 |
2012-03-01 |
Pharmacyclics, Inc. |
Btk inhibitors for the treatment of immune mediated conditions
|
EP2590982B1
(en)
*
|
2010-07-09 |
2017-08-23 |
The Walter and Eliza Hall Institute of Medical Research |
Protein kinase inhibitors and methods of treatment
|
CN103096716B
(zh)
|
2010-08-10 |
2016-03-02 |
西建阿维拉米斯研究公司 |
Btk抑制剂的苯磺酸盐
|
JP5749341B2
(ja)
*
|
2010-08-20 |
2015-07-15 |
ハチソン メディファーマ リミテッド |
ピロロピリミジン化合物およびその使用
|
JP5957460B2
(ja)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
複素環式化合物またはその使用
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
WO2012064706A1
(en)
|
2010-11-10 |
2012-05-18 |
Avila Therapeutics, Inc. |
Mutant-selective egfr inhibitors and uses thereof
|
EA022586B1
(ru)
|
2011-02-23 |
2016-01-29 |
Пфайзер Инк. |
ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
US20140107151A1
(en)
*
|
2011-05-17 |
2014-04-17 |
Principia Biophama Inc. |
Tyrosine kinase inhibitors
|
ES2604191T3
(es)
*
|
2011-05-17 |
2017-03-03 |
Principia Biopharma Inc. |
Inhibidores de tirosina quinasas
|
DK2710007T3
(da)
|
2011-05-17 |
2020-01-27 |
Principia Biopharma Inc |
Kinasehæmmere
|
BR112013033534A2
(pt)
*
|
2011-06-28 |
2017-02-07 |
Pharmacyclics Inc |
métodos e composições para inibição de reabsorção de osso
|
WO2013006443A2
(en)
|
2011-07-01 |
2013-01-10 |
Dana-Farber Cancer Institute, Inc. |
Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
|
KR20140058543A
(ko)
|
2011-07-08 |
2014-05-14 |
노파르티스 아게 |
신규 피롤로 피리미딘 유도체
|
AU2012283775A1
(en)
|
2011-07-13 |
2014-01-23 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
PE20141681A1
(es)
|
2011-07-19 |
2014-11-14 |
Merck Sharp And Dohme B V |
Inhibidores de btk
|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
EP2771010A4
(en)
*
|
2011-10-19 |
2015-04-01 |
Pharmacyclics Inc |
USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK)
|
EP2770830A4
(en)
|
2011-10-28 |
2015-05-27 |
Celgene Avilomics Res Inc |
METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE)
|
GB2496135B
(en)
|
2011-11-01 |
2015-03-18 |
Valirx Plc |
Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis
|
US8722676B2
(en)
*
|
2011-11-03 |
2014-05-13 |
Genentech, Inc. |
Bicyclic piperazine compounds
|
UA111756C2
(uk)
*
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
US9212381B2
(en)
*
|
2011-11-10 |
2015-12-15 |
President And Fellows Of Harvard College |
Methods and compositions for labeling polypeptides
|
WO2013074986A1
(en)
|
2011-11-17 |
2013-05-23 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
KR101636631B1
(ko)
|
2011-11-29 |
2016-07-05 |
오노 야꾸힝 고교 가부시키가이샤 |
퓨리논 유도체 염산염
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
DK2802328T3
(en)
|
2012-01-09 |
2018-06-14 |
X Chem Inc |
TRYPTOLIN DERIVATIVES WITH KINASE INHIBITIVE ACTIVITY AND APPLICATIONS THEREOF
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
CN104080789B
(zh)
*
|
2012-01-31 |
2016-05-11 |
南京奥昭生物科技有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
TW201336847A
(zh)
*
|
2012-02-07 |
2013-09-16 |
Taiho Pharmaceutical Co Ltd |
喹啉基吡咯并嘧啶化合物或其鹽
|
JP5557963B2
(ja)
*
|
2012-02-23 |
2014-07-23 |
大鵬薬品工業株式会社 |
キノリルピロロピリミジル縮合環化合物又はその塩
|
CN103312670A
(zh)
|
2012-03-12 |
2013-09-18 |
西安西电捷通无线网络通信股份有限公司 |
一种认证方法及系统
|
EP2825041B1
(en)
|
2012-03-15 |
2021-04-21 |
Celgene CAR LLC |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
MY185243A
(en)
|
2012-03-15 |
2021-04-30 |
Celgene Car Llc |
Salts of an epidermal growth factor receptor kinase inhibitor
|
US9365566B2
(en)
|
2012-03-27 |
2016-06-14 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives
|
US9353062B2
(en)
|
2012-04-04 |
2016-05-31 |
Hangzhouderenyucheng Biotechnology Ltd |
Substituted quinolines as bruton's tyrosine kinases inhibitors
|
ES2681050T3
(es)
|
2012-04-11 |
2018-09-11 |
Acerta Pharma B.V. |
Inhibidores de la tirosina quinasa de Bruton para la movilización hematopoyética
|
US9879003B2
(en)
|
2012-04-11 |
2018-01-30 |
Dana-Farber Cancer Institute, Inc. |
Host targeted inhibitors of dengue virus and other viruses
|
CN103374001B
(zh)
*
|
2012-04-19 |
2015-10-28 |
山东轩竹医药科技有限公司 |
咪唑并三嗪类mTOR抑制剂
|
CA2874211A1
(en)
*
|
2012-05-31 |
2013-12-05 |
Pharmascience Inc. |
Protein kinase inhibitors
|
EP2854859A4
(en)
*
|
2012-06-04 |
2016-01-13 |
Pharmacyclics Inc |
CRYSTALLINE FORMS OF A BRUTON TYROSINE KINASE HEATHER
|
AR091273A1
(es)
*
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
MX368112B
(es)
*
|
2012-06-18 |
2019-09-18 |
Principia Biopharma Inc |
Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias.
|
US20150140085A1
(en)
|
2012-06-29 |
2015-05-21 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
WO2014018567A1
(en)
|
2012-07-24 |
2014-01-30 |
Pharmacyclics, Inc. |
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
|
JP6261580B2
(ja)
*
|
2012-07-30 |
2018-01-17 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化イブルチニブ
|
WO2014022569A1
(en)
*
|
2012-08-03 |
2014-02-06 |
Principia Biopharma Inc. |
Treatment of dry eye
|
US20140045813A1
(en)
|
2012-08-10 |
2014-02-13 |
Boehringer Ingelheim International Gmbh |
Heteroaromatic compounds as btk inhibitors
|
CN103121999A
(zh)
*
|
2012-08-29 |
2013-05-29 |
苏州迪飞医药科技有限公司 |
一种酪氨酸激酶抑制剂pci-32765的合成方法
|
WO2014036016A1
(en)
|
2012-08-31 |
2014-03-06 |
Principia Biopharma Inc. |
Benzimidazole derivatives as itk inhibitors
|
ES2731833T3
(es)
*
|
2012-09-10 |
2019-11-19 |
Principia Biopharma Inc |
Compuestos pirazolopirimidínicos comos inhibidores de cinasas
|
CH706997A1
(en)
|
2012-09-20 |
2014-03-31 |
Ferag Ag |
Access control on operating modules of a control unit.
|
WO2014063068A1
(en)
|
2012-10-18 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
CN111329989A
(zh)
*
|
2012-11-02 |
2020-06-26 |
药品循环有限责任公司 |
Tec家族激酶抑制剂辅助疗法
|
SG11201502893WA
(en)
|
2012-11-02 |
2015-05-28 |
Pfizer |
Bruton's tyrosine kinase inhibitors
|
EA201590855A1
(ru)
|
2012-11-15 |
2015-11-30 |
Фармасайкликс, Инк. |
Соединения пирролопиримидина как ингибиторы киназ
|
ES2605856T3
(es)
|
2012-11-16 |
2017-03-16 |
Bristol-Myers Squibb Company |
Moduladores GPR40 de dihidropirazol
|
CN103848810A
(zh)
*
|
2012-11-30 |
2014-06-11 |
北京赛林泰医药技术有限公司 |
鲁顿酪氨酸激酶抑制剂
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
WO2014100639A1
(en)
*
|
2012-12-21 |
2014-06-26 |
Teva Pharmaceutical Industries Ltd. |
Transmucosal delivery of glatiramer acetate
|
WO2014113942A1
(en)
*
|
2013-01-23 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
WO2014113932A1
(en)
*
|
2013-01-23 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
US20140206681A1
(en)
|
2013-01-23 |
2014-07-24 |
Ronald M. Kim |
Btk inhibitors
|
CA2900012A1
(en)
|
2013-02-08 |
2014-08-14 |
Celgene Avilomics Research, Inc. |
Erk inhibitors and uses thereof
|
WO2014130856A2
(en)
*
|
2013-02-21 |
2014-08-28 |
Wayne Rothbaum |
Treatment of skeletal-related disorders
|
MX2015010934A
(es)
|
2013-02-22 |
2015-10-29 |
Taiho Pharmaceutical Co Ltd |
Metodo para producir un compuesto triciclico, y un compuesto triciclico capaz de producirse por dicho metodo de produccion.
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
WO2014165253A1
(en)
*
|
2013-03-12 |
2014-10-09 |
Nbip, Llc |
Compositions and methods for preventing infection of a wound and for advancing the healing process
|
CN103142601A
(zh)
*
|
2013-03-13 |
2013-06-12 |
杭州雷索药业有限公司 |
Pci-32765在制备抗血管生成类药物中的应用
|
JP2016512549A
(ja)
*
|
2013-03-14 |
2016-04-28 |
ファーマサイクリックス エルエルシー |
ブルトン型チロシンキナーゼ阻害剤及びcyp3a4阻害剤の組み合わせ
|
CN108997225A
(zh)
|
2013-03-14 |
2018-12-14 |
特雷罗药物股份有限公司 |
Jak2和alk2抑制剂及其使用方法
|
US8895750B2
(en)
|
2013-03-14 |
2014-11-25 |
Boehringer Ingelheim International Gmbh |
Heteroaromatic compounds as BTK inhibitors
|
JP6495886B2
(ja)
|
2013-03-15 |
2019-04-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Btk阻害剤としての複素環式芳香族化合物
|
US9156847B2
(en)
|
2013-03-15 |
2015-10-13 |
Janssen Pharmaceutica Nv |
Processes and intermediates for preparing a medicament
|
MX2015012731A
(es)
*
|
2013-03-15 |
2016-02-18 |
Janssen Pharmaceutica Nv |
Procesos e intermedios para preparar un medicamento.
|
KR20150133172A
(ko)
|
2013-03-15 |
2015-11-27 |
셀진 아빌로믹스 리서치, 인코포레이티드 |
Mk2 억제제 및 이의 용도
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
WO2014168975A1
(en)
*
|
2013-04-08 |
2014-10-16 |
Pharmacyclics, Inc. |
Ibrutinib combination therapy
|
EP2983674A4
(en)
|
2013-04-08 |
2017-05-10 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
AU2014256633B2
(en)
|
2013-04-25 |
2017-02-02 |
Beigene Switzerland Gmbh |
Fused heterocyclic compounds as protein kinase inhibitors
|
GB2513615A
(en)
|
2013-05-01 |
2014-11-05 |
Cancer Rec Tech Ltd |
Medical use
|
GB201309085D0
(en)
|
2013-05-20 |
2013-07-03 |
Redx Pharma Ltd |
Compounds
|
US9694011B2
(en)
|
2013-05-21 |
2017-07-04 |
Jiangsu Medolution Ltd |
Substituted pyrazolopyrimidines as kinases inhibitors
|
JP6458018B2
(ja)
|
2013-07-02 |
2019-01-23 |
ファーマサイクリックス エルエルシー |
キナーゼ阻害剤としてのプリノン化合物
|
RU2016101548A
(ru)
|
2013-07-03 |
2017-08-08 |
Ф. Хоффманн-Ля Рош Аг |
Соединения амидов гетероарилпиридона и азапиридона
|
WO2015013579A1
(en)
|
2013-07-26 |
2015-01-29 |
Update Pharma Inc. |
Compositions to improve the therapeutic benefit of bisantrene
|
EP2832358A1
(en)
|
2013-08-02 |
2015-02-04 |
Bionsil S.r.l. |
Pharmaceutical kit for use in the treatment of colon and colorectal cancer
|
JP6800750B2
(ja)
|
2013-08-02 |
2020-12-16 |
ファーマサイクリックス エルエルシー |
固形腫瘍の処置方法
|
EP3033079B1
(en)
|
2013-08-12 |
2018-10-31 |
Pharmacyclics LLC |
Methods for the treatment of her2 amplified cancer
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
CN112457403B
(zh)
|
2013-09-13 |
2022-11-29 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
TN2016000094A1
(en)
*
|
2013-09-30 |
2017-07-05 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase.
|
US20150105409A1
(en)
*
|
2013-10-10 |
2015-04-16 |
Acetylon Pharmaceticals, Inc. |
Hdac inhibitors, alone or in combination with btk inhibitors, for treating nonhodgkin's lymphoma
|
CN104341388B
(zh)
|
2013-10-16 |
2017-03-22 |
北京诺诚健华医药科技有限公司 |
芳香族酰胺类衍生物、其制备方法及其在医药上的应用
|
WO2015057992A1
(en)
|
2013-10-16 |
2015-04-23 |
Izumi Raquel |
Btk inhibitors for hematopoietic mobilization
|
WO2015069441A1
(en)
*
|
2013-10-18 |
2015-05-14 |
Medivation Technologies, Inc. |
Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
|
EP3057970A1
(en)
|
2013-10-18 |
2016-08-24 |
Medivation Technologies, Inc. |
Heterocyclic compounds and methods of use
|
AU2014337044A1
(en)
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
EP3060251A4
(en)
*
|
2013-10-25 |
2017-12-06 |
Pharmacyclics LLC |
Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
|
CN111265531B
(zh)
*
|
2013-10-25 |
2023-11-10 |
药品循环有限责任公司 |
治疗和预防移植物抗宿主病的方法
|
US9636340B2
(en)
|
2013-11-12 |
2017-05-02 |
Ayyappan K. Rajasekaran |
Kinase inhibitors
|
WO2015071432A1
(en)
|
2013-11-14 |
2015-05-21 |
Sandoz Ag |
Pharmaceutical compositions of ibrutinib
|
WO2015073833A1
(en)
*
|
2013-11-15 |
2015-05-21 |
Pharmacyclics, Inc. |
Methods for delaying or preventing the onset of type 1 diabetes
|
CN103626774B
(zh)
|
2013-11-20 |
2015-11-04 |
苏州明锐医药科技有限公司 |
伊鲁替尼的制备方法
|
CA2833867A1
(en)
*
|
2013-11-21 |
2015-05-21 |
Pharmascience Inc. |
Protein kinase inhibitors
|
CN103694241A
(zh)
|
2013-11-27 |
2014-04-02 |
苏州晶云药物科技有限公司 |
Pci-32765的新晶型a及其制备方法
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
CN105939717B
(zh)
*
|
2013-12-02 |
2019-09-13 |
药品循环有限责任公司 |
治疗和预防同种抗体驱动的慢性移植物抗宿主病的方法
|
ME02883B
(me)
|
2013-12-05 |
2018-04-20 |
Pfizer |
PIROLO[2,3-d]PIRIMIDINIL-, PIROLO[2,3-b]PIRAZINIL- I PIROLO[2,3-d] PIRIDINILAKRILAMIDI
|
CA2929918C
(en)
|
2013-12-05 |
2018-01-23 |
F. Hoffmann-La Roche Ag |
Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
|
CA2931431A1
(en)
|
2013-12-05 |
2015-06-11 |
Acerta Pharma B.V. |
Therapeutic combination of a pi3k inhibitor and a btk inhibitor
|
US9908872B2
(en)
*
|
2013-12-13 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
CA2932351A1
(en)
|
2013-12-13 |
2015-06-18 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
WO2015095102A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
US9637486B2
(en)
|
2013-12-20 |
2017-05-02 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
US10272083B2
(en)
|
2014-01-21 |
2019-04-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
|
CN106008515A
(zh)
*
|
2014-01-29 |
2016-10-12 |
苏州晶云药物科技有限公司 |
依鲁替尼的新晶型及其制备方法
|
EP3099674B1
(en)
|
2014-01-29 |
2018-10-24 |
Boehringer Ingelheim International Gmbh |
Pyrazole compounds as btk inhibitors
|
CN105916859A
(zh)
*
|
2014-02-03 |
2016-08-31 |
卡迪拉保健有限公司 |
杂环化合物
|
US10092569B2
(en)
|
2014-02-21 |
2018-10-09 |
Principia Biopharma Inc. |
Salts and solid form of a BTK inhibitor
|
EP3110820B1
(en)
|
2014-02-28 |
2022-04-06 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
EP3119910A4
(en)
|
2014-03-20 |
2018-02-21 |
Pharmacyclics LLC |
Phospholipase c gamma 2 and resistance associated mutations
|
GB201404987D0
(en)
*
|
2014-03-20 |
2014-05-07 |
Redx Pharma Ltd |
Compounds
|
WO2015146159A1
(en)
|
2014-03-25 |
2015-10-01 |
Ono Pharmaceutical Co., Ltd. |
Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
|
WO2015151006A1
(en)
*
|
2014-03-29 |
2015-10-08 |
Lupin Limited |
Substituted purine compounds as btk inhibitors
|
WO2015181633A2
(en)
|
2014-04-11 |
2015-12-03 |
Acerta Pharma B.V. |
Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
WO2015185998A2
(en)
|
2014-04-11 |
2015-12-10 |
Acerta Pharma B.V. |
Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
|
CN105017256A
(zh)
*
|
2014-04-29 |
2015-11-04 |
浙江导明医药科技有限公司 |
多氟化合物作为布鲁顿酪氨酸激酶抑制剂
|
CN105085474B
(zh)
*
|
2014-05-07 |
2018-05-18 |
北京赛林泰医药技术有限公司 |
鲁顿酪氨酸激酶抑制剂
|
CN105085529A
(zh)
*
|
2014-05-15 |
2015-11-25 |
广东东阳光药业有限公司 |
依鲁替尼新晶型及其制备方法
|
CN104086551B
(zh)
*
|
2014-06-06 |
2016-09-21 |
人福医药集团股份公司 |
化合物及其制备方法和用途
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
WO2015193740A2
(en)
|
2014-06-17 |
2015-12-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
|
CN104945404B
(zh)
*
|
2014-06-25 |
2018-09-14 |
广东东阳光药业有限公司 |
一种n-丙烯羰基哌啶衍生物的制备方法
|
WO2016004305A2
(en)
|
2014-07-02 |
2016-01-07 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
CN105294571B
(zh)
*
|
2014-07-03 |
2019-04-23 |
浙江九洲药业股份有限公司 |
一种依鲁替尼中间体及其制备方法和用途
|
EP3166608B1
(en)
|
2014-07-07 |
2018-12-12 |
Jiangsu Hengrui Medicine Co., Ltd. |
Aminopyridazinone compounds as protein kinase inhibitors
|
TW201607930A
(zh)
*
|
2014-07-18 |
2016-03-01 |
百濟神州有限公司 |
作為t790m/wt-egfr的選擇性和不可逆的激酶抑制劑的5-氨基-4-氨甲醯基-吡唑化合物及其用途
|
WO2016019237A2
(en)
*
|
2014-07-31 |
2016-02-04 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
WO2016019233A1
(en)
*
|
2014-08-01 |
2016-02-04 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
AU2015300798A1
(en)
|
2014-08-07 |
2017-02-02 |
Pharmacyclics Llc |
Novel formulations of a Bruton's tyrosine kinase inhibitor
|
AR101476A1
(es)
|
2014-08-07 |
2016-12-21 |
Acerta Pharma Bv |
Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
|
CN105461720B
(zh)
*
|
2014-08-08 |
2019-08-06 |
南京圣和药业股份有限公司 |
吗啉类酪氨酸激酶抑制剂
|
AU2015300966A1
(en)
|
2014-08-08 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Bruton's tyrosine kinase inhibitor combinations and uses thereof
|
DK3179992T3
(da)
|
2014-08-11 |
2022-07-11 |
Acerta Pharma Bv |
Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor
|
HUE056329T2
(hu)
|
2014-08-11 |
2022-02-28 |
Acerta Pharma Bv |
BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi
|
TW201618774A
(zh)
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
使用btk抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
|
US20170224819A1
(en)
|
2014-08-11 |
2017-08-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
|
EP3180349A4
(en)
|
2014-08-12 |
2018-08-22 |
Monash University |
Lymph directing prodrugs
|
ES2741785T3
(es)
|
2014-08-13 |
2020-02-12 |
Celgene Car Llc |
Formas y composiciones de un inhibidor de ERK
|
EP3180343A1
(en)
|
2014-08-14 |
2017-06-21 |
Assia Chemical Industries Ltd. |
Solid state forms of ibrutinib
|
EP3201186B1
(en)
|
2014-10-02 |
2019-02-27 |
F. Hoffmann-La Roche AG |
Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
|
WO2016065138A1
(en)
|
2014-10-22 |
2016-04-28 |
Dana-Farber Cancer Institute, Inc. |
Thiazolyl-containing compounds for treating proliferative diseases
|
PL3209656T3
(pl)
|
2014-10-24 |
2020-12-14 |
Bristol-Myers Squibb Company |
Związki indolo-karboksyamidu użyteczne jako inhibitory kinazy
|
CN107108604B
(zh)
|
2014-10-27 |
2020-07-24 |
豪夫迈·罗氏有限公司 |
制备三环内酰胺化合物的方法
|
WO2016066673A1
(en)
*
|
2014-10-30 |
2016-05-06 |
Sandoz Ag |
Synthesis of substituted 1h-pyrazolo[3,4-d]pyrimidines
|
US10196397B2
(en)
|
2014-11-19 |
2019-02-05 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of ibrutinib
|
WO2016079216A1
(en)
|
2014-11-20 |
2016-05-26 |
Sandoz Ag |
Physical forms of ibrutinib, a bruton's kinase inhibitor
|
CN104447761A
(zh)
*
|
2014-11-27 |
2015-03-25 |
广东东阳光药业有限公司 |
一种吡唑衍生物的制备方法
|
AR102871A1
(es)
|
2014-12-03 |
2017-03-29 |
Pharmacyclics Llc |
Métodos de tratamiento de fibrosis
|
WO2016088074A1
(en)
*
|
2014-12-03 |
2016-06-09 |
Dr. Reddy’S Laboratories Limited |
Process for the preparation of amorphous ibrutinib
|
WO2016087994A1
(en)
|
2014-12-05 |
2016-06-09 |
Acerta Pharma B.V. |
Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
|
CN104478884A
(zh)
*
|
2014-12-05 |
2015-04-01 |
广东东阳光药业有限公司 |
一种中间体的制备方法
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
MX2017007973A
(es)
|
2014-12-18 |
2018-02-09 |
Principia Biopharma Inc |
Tratamiento de penfigo.
|
AU2015367509B2
(en)
|
2014-12-18 |
2020-01-02 |
F. Hoffmann-La Roche Ag |
Tetrahydro-pyrido(3,4-b)indole estrogen receptor modulators and uses thereof
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2016106628A1
(en)
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
WO2016106652A1
(en)
*
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Biarylether imidazopyrazine btk inhibitors
|
WO2016106624A1
(en)
*
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Tertiary alcohol imidazopyrazine btk inhibitors
|
WO2016106629A1
(en)
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
CN105820168B
(zh)
*
|
2015-01-09 |
2018-12-04 |
上海医药工业研究院 |
一种依鲁替尼中间体的制备方法
|
MA41350A
(fr)
*
|
2015-01-14 |
2017-11-21 |
Janssen Pharmaceutica Nv |
Synthèse d'un inhibiteur de la tyrosine kinase de bruton
|
US10266535B2
(en)
|
2015-01-21 |
2019-04-23 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Inhibitor of FLT3 kinase and use thereof
|
WO2016123504A1
(en)
*
|
2015-01-30 |
2016-08-04 |
Pharmacyclics Llc |
Btk inhibitor combinations and multidrug-resistance
|
CZ201584A3
(cs)
|
2015-02-09 |
2016-08-17 |
Zentiva, K.S. |
Sůl Ibrutinib sulfátu
|
CN107207519B
(zh)
*
|
2015-02-12 |
2019-11-08 |
正大天晴药业集团股份有限公司 |
伊布替尼的制备方法
|
WO2016132383A1
(en)
*
|
2015-02-18 |
2016-08-25 |
Mylan Laboratories Limited |
Process for the preparation of ibrutinib
|
WO2016138352A1
(en)
|
2015-02-27 |
2016-09-01 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
CA3177990A1
(en)
*
|
2015-03-03 |
2016-09-09 |
Pharmacyclics Llc |
Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
|
WO2016141044A1
(en)
|
2015-03-04 |
2016-09-09 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Erbb4 inhibitors and methods of use thereof
|
CN106146508A
(zh)
*
|
2015-03-19 |
2016-11-23 |
浙江导明医药科技有限公司 |
优化的联合用药及其治疗癌症和自身免疫疾病的用途
|
US9717745B2
(en)
|
2015-03-19 |
2017-08-01 |
Zhejiang DTRM Biopharma Co. Ltd. |
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
|
EP3273966B1
(en)
|
2015-03-27 |
2023-05-03 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
WO2016161248A1
(en)
*
|
2015-04-02 |
2016-10-06 |
Tolero Pharmaceuticals, Inc. |
Targeting pim kinases in combination with btk inhibition
|
WO2016156127A1
(en)
|
2015-04-02 |
2016-10-06 |
Ratiopharm Gmbh |
Co-crystals of ibrutinib with carboxylic acids
|
CN106146511A
(zh)
*
|
2015-04-03 |
2016-11-23 |
安润医药科技(苏州)有限公司 |
吡唑并嘧啶衍生物、制备方法、药物组合物及用途
|
CN105906621A
(zh)
*
|
2015-04-06 |
2016-08-31 |
四川百利药业有限责任公司 |
用作fgfr抑制剂的乙醇类化合物
|
CA2981601A1
(en)
|
2015-04-06 |
2016-10-13 |
Janssen Pharmaceutica Nv |
Compositions containing ibrutinib
|
LT3280729T
(lt)
|
2015-04-08 |
2022-08-10 |
Novartis Ag |
Terapijos cd20, terapijos cd22 ir kombinuotos terapijos su cd19 chimerinį antigeno receptorių (car) ekspresuojančia ląstele
|
EP3281943B1
(en)
|
2015-04-09 |
2023-06-28 |
ONO Pharmaceutical Co., Ltd. |
Process for producing purinone derivative
|
CN106146512B
(zh)
*
|
2015-04-09 |
2018-07-17 |
北京睿创康泰医药研究院有限公司 |
依鲁替尼的制备方法
|
US10485794B2
(en)
|
2015-04-13 |
2019-11-26 |
Daiichi Sankyo Company, Limited |
Treatment method by combined use of MDM2 inhibitor and BTK inhibitor
|
CN106146482B
(zh)
*
|
2015-04-14 |
2020-06-23 |
宁波文达医药科技有限公司 |
布鲁顿酪氨酸激酶抑制剂
|
WO2016170545A1
(en)
*
|
2015-04-22 |
2016-10-27 |
Msn Laboratories Private Limited |
Process for the preparation of 1-[(3r)-3-[4-amino-3-(4-phenoxyphenvl)-1h- pvrazolo[3,4-d]pyriniidin-1-y1]-1-piperidinvl]-2-propen-1-one and its polymorphs thereof
|
TW201701879A
(zh)
|
2015-04-30 |
2017-01-16 |
拜耳製藥公司 |
Irak4抑制劑組合
|
EP3195865A1
(de)
|
2016-01-25 |
2017-07-26 |
Bayer Pharma Aktiengesellschaft |
Kombinationen von irak4 inhibitoren und btk inhibitoren
|
CN114601931B
(zh)
|
2015-05-26 |
2023-09-01 |
莫佛塞斯公司 |
抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途
|
HUE055419T2
(hu)
|
2015-06-03 |
2021-11-29 |
Principia Biopharma Inc |
Tirozinkináz-inhibitorok
|
CA2986441A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
US9394312B1
(en)
*
|
2015-06-14 |
2016-07-19 |
Mark Quang Nguyen |
Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use
|
BR112017027951A2
(pt)
|
2015-06-22 |
2018-08-28 |
Ono Pharmaceutical Co., Ltd. |
composto inibitório de brk
|
MA42242A
(fr)
|
2015-06-24 |
2018-05-02 |
Principia Biopharma Inc |
Inhibiteurs de la tyrosine kinase
|
CZ2015442A3
(cs)
*
|
2015-06-26 |
2017-01-04 |
Zentiva, K.S. |
Ibrutinib hemisulfát
|
WO2016207172A1
(en)
*
|
2015-06-26 |
2016-12-29 |
Sandoz Gmbh |
Preparation of pure amorphous ibrutinib
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
CN111848643A
(zh)
|
2015-07-02 |
2020-10-30 |
豪夫迈·罗氏有限公司 |
苯并氧氮杂*噁唑烷酮化合物及其使用方法
|
KR102014326B1
(ko)
|
2015-07-02 |
2019-08-26 |
에프. 호프만-라 로슈 아게 |
벤즈옥사제핀 옥사졸리디논 화합물 및 사용 방법
|
PT3954690T
(pt)
|
2015-07-02 |
2023-06-06 |
Acerta Pharma Bv |
Formas sólidas e formulações de (s)-4-(8-amino-3-(1-(but- 2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n- (piridin-2-il)benzamida
|
ITUB20152576A1
(it)
*
|
2015-07-29 |
2017-01-29 |
Laboratorio Chimico Int S P A |
Procedimento per la preparazione di ibrutinib e nuovo intermedio di sintesi.
|
EP3337485B1
(en)
|
2015-08-19 |
2021-03-17 |
Sun Pharmaceutical Industries Ltd |
Crystalline forms of ibrutinib
|
US20190008859A1
(en)
|
2015-08-21 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
|
CA2996177A1
(en)
|
2015-08-31 |
2017-03-09 |
Pharmacyclics Llc |
Btk inhibitor combinations for treating multiple myeloma
|
JP6802263B2
(ja)
|
2015-09-02 |
2020-12-16 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用
|
WO2017041139A1
(en)
|
2015-09-08 |
2017-03-16 |
Monash University |
Lymph directing prodrugs
|
EP3347018B1
(en)
|
2015-09-09 |
2021-09-01 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
CN105753863B
(zh)
*
|
2015-09-11 |
2018-07-31 |
东莞市真兴贝特医药技术有限公司 |
氧代二氢咪唑并吡啶类化合物及其应用
|
CA2904270A1
(en)
*
|
2015-09-11 |
2017-03-11 |
Pharmascience Inc. |
Protein kinase inhibitors
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
US10611766B2
(en)
|
2015-09-16 |
2020-04-07 |
Loxo Oncology Inc. |
Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
|
JP2018530550A
(ja)
|
2015-10-01 |
2018-10-18 |
ギリアド サイエンシズ, インコーポレイテッド |
癌を治療するためのbtk阻害剤とチェックポイント阻害剤との組合せ
|
CN106608877B
(zh)
*
|
2015-10-21 |
2018-11-13 |
新发药业有限公司 |
一种依鲁替尼中间体4-氨基-3-(4-苯氧基)苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
|
DK3364958T3
(da)
|
2015-10-23 |
2023-04-11 |
Navitor Pharm Inc |
Modulatorer af sestrin-gator2-interaktion og anvendelser deraf
|
US9834561B2
(en)
|
2015-10-28 |
2017-12-05 |
Scinopharm Taiwan, Ltd. |
Process for preparing ibrutinib and its intermediates
|
CN108884076B
(zh)
|
2015-11-17 |
2021-07-30 |
默克专利有限公司 |
使用具有btk抑制活性的嘧啶和吡啶化合物治疗多发性硬化症的方法
|
CN105294696A
(zh)
*
|
2015-11-19 |
2016-02-03 |
上海创诺医药集团有限公司 |
依鲁替尼新晶型及其制备方法
|
WO2017096303A2
(en)
|
2015-12-04 |
2017-06-08 |
Portola Pharmaceuticals, Inc. |
Cerdulatinib for treating hematological cancers
|
MA43377A
(fr)
|
2015-12-04 |
2021-05-19 |
Hutchinson Fred Cancer Res |
Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
|
JO3793B1
(ar)
|
2015-12-10 |
2021-01-31 |
Janssen Pharmaceutica Nv |
مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
|
JO3794B1
(ar)
|
2015-12-10 |
2021-01-31 |
Janssen Pharmaceutica Nv |
المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
|
WO2017106352A1
(en)
|
2015-12-14 |
2017-06-22 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of mthfd2 and uses thereof
|
SI3390395T1
(sl)
|
2015-12-16 |
2020-11-30 |
Loxo Oncology, Inc. |
Spojine uporabne kot inhibitorji kinaz
|
WO2017106429A2
(en)
|
2015-12-16 |
2017-06-22 |
Boehringer Ingelheim International Gmbh |
Heteroaromatic compounds as btk inhibitors
|
WO2017122175A1
(en)
|
2016-01-13 |
2017-07-20 |
Acerta Pharma B.V. |
Therapeutic combinations of an antifolate and a btk inhibitor
|
JP6916185B2
(ja)
|
2016-01-13 |
2021-08-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Btk阻害剤としてのイソキノロン類
|
KR20180101521A
(ko)
|
2016-01-19 |
2018-09-12 |
얀센 파마슈티카 엔.브이. |
Btk 저해제를 포함하는 제형/조성물
|
CN114681462A
(zh)
|
2016-01-19 |
2022-07-01 |
詹森药业有限公司 |
包含btk抑制剂的配制品/组合物
|
US10793566B2
(en)
|
2016-01-21 |
2020-10-06 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
IL260691B
(en)
*
|
2016-01-21 |
2022-07-01 |
Zibo Biopolar Changsheng Pharmaceutical Co Ltd |
Burton Tyrosine Kinase Tracers
|
CN105732638B
(zh)
*
|
2016-01-22 |
2018-01-30 |
成都倍特药业有限公司 |
一种具有螺环或桥环结构的布鲁顿酪氨酸激酶抑制剂及其制备方法
|
CN106995446B
(zh)
*
|
2016-01-22 |
2021-07-02 |
山东新时代药业有限公司 |
布鲁顿酪氨酸激酶抑制剂制备方法
|
US10626117B2
(en)
|
2016-02-01 |
2020-04-21 |
Natco Pharma Limited |
Process for the preparation of Ibrutinib
|
WO2017134685A2
(en)
*
|
2016-02-02 |
2017-08-10 |
Sun Pharma Advanced Research Company Limited |
Novel hydrazino compounds as btk inhibitors
|
US10435409B2
(en)
|
2016-02-04 |
2019-10-08 |
Shilpa Medicare Limited |
Process for the preparation of ibrutinib
|
CN108602834B
(zh)
*
|
2016-02-05 |
2021-01-08 |
北京盛诺基医药科技股份有限公司 |
一种布鲁顿酪氨酸激酶抑制剂
|
GB2558514A
(en)
*
|
2016-02-09 |
2018-07-18 |
Azad Pharmaceutical Ingredients Ag |
Process for the synthesis of stable amorphous ibrutinib
|
CA3015172A1
(en)
|
2016-02-18 |
2017-08-24 |
Privo Technologies, Inc. |
Two-stage microparticle-based therapeutic delivery system and method
|
CN105646498A
(zh)
*
|
2016-03-01 |
2016-06-08 |
孙霖 |
依鲁替尼晶型f及制备方法
|
CN105646499A
(zh)
*
|
2016-03-01 |
2016-06-08 |
孙霖 |
依鲁替尼晶型g及制备方法
|
RS62271B1
(sr)
|
2016-03-09 |
2021-09-30 |
Raze Therapeutics Inc |
Inhibitori 3-fosfoglicerat dehidrogenaze i njihova upotreba
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
WO2017156495A1
(en)
|
2016-03-11 |
2017-09-14 |
Corvus Pharmaceuticals, Inc. |
Compounds and methods for modulating bruton's tyrosine kinase
|
WO2017163257A1
(en)
*
|
2016-03-21 |
2017-09-28 |
Ind-Swift Laboratories Limited |
Process for preparing pure lh-pyrazolo[3,4-d] pyrimidine derivative
|
EP3436447B1
(en)
|
2016-03-31 |
2021-07-14 |
Takeda Pharmaceutical Company Limited |
Isoquinolinyl triazolone complexes
|
CZ2016196A3
(cs)
|
2016-04-06 |
2017-10-18 |
Zentiva, K.S. |
Pevné formy Ibrutinibu
|
WO2017177230A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
EP3960180A1
(en)
|
2016-04-15 |
2022-03-02 |
Cancer Research Technology Limited |
Heterocyclic compounds as ret kinase inhibitors
|
DK3442535T3
(da)
|
2016-04-15 |
2022-09-05 |
Cancer Research Tech Ltd |
Heterocykliske stoffer som as ret-kinase-hæmmere
|
WO2017184774A1
(en)
|
2016-04-19 |
2017-10-26 |
Acetylon Pharmaceuticals, Inc. |
Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia
|
AU2017258510A1
(en)
*
|
2016-04-29 |
2018-10-11 |
Dana-Farber Cancer Institute, Inc. |
HCK as a therapeutic target in MYD88 mutated diseases
|
CZ2016276A3
(cs)
|
2016-05-11 |
2017-11-22 |
Zentiva, K.S. |
Pevné formy volné báze ibrutinibu
|
BR112018073781A2
(pt)
|
2016-05-20 |
2019-02-26 |
Biohaven Pharmaceutical Holding Company Ltd. |
uso de agentes de modulação de glutamato com imunoterapias para o tratamento de câncer
|
CN105859728B
(zh)
*
|
2016-05-26 |
2018-06-08 |
江苏中邦制药有限公司 |
一种依鲁替尼的制备方法
|
CN109640964A
(zh)
|
2016-05-27 |
2019-04-16 |
Tg治疗有限公司 |
用于治疗B细胞增殖性紊乱的抗-CD20抗体、P13激酶-δ选择性抑制剂和BTK抑制剂的组合
|
US20170362228A1
(en)
|
2016-06-16 |
2017-12-21 |
Genentech, Inc. |
TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
|
WO2017216279A1
(en)
|
2016-06-16 |
2017-12-21 |
F. Hoffmann-La Roche Ag |
Heteroaryl estrogen receptor modulators and uses thereof
|
WO2017219948A1
(en)
*
|
2016-06-20 |
2017-12-28 |
Novartis Ag |
Crystalline forms of triazolopyrimidine compound
|
EP3808748A1
(en)
|
2016-06-21 |
2021-04-21 |
X4 Pharmaceuticals, Inc. |
Substituted piperidines as cxcr4-inhibitors
|
CA3027500A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
CA3027495A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
WO2018000250A1
(zh)
*
|
2016-06-29 |
2018-01-04 |
上海创诺医药集团有限公司 |
依鲁替尼新晶型及其制备方法
|
CN106117214A
(zh)
*
|
2016-06-29 |
2016-11-16 |
上海创诺医药集团有限公司 |
依鲁替尼新晶型及其制备方法
|
AU2017290354C1
(en)
|
2016-06-29 |
2023-07-06 |
Principia Biopharma Inc. |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
EP3478687B1
(en)
|
2016-06-30 |
2024-03-20 |
Daewoong Pharmaceutical Co., Ltd. |
Pyrazolopyrimidine derivatives as kinase inhibitor
|
WO2018002958A1
(en)
|
2016-06-30 |
2018-01-04 |
Sun Pharma Advanced Research Company Limited |
Novel hydrazide containing compounds as btk inhibitors
|
US10864203B2
(en)
|
2016-07-05 |
2020-12-15 |
Beigene, Ltd. |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
CN109153680B
(zh)
*
|
2016-07-07 |
2021-04-23 |
株式会社大熊制药 |
4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物
|
CN107641123A
(zh)
*
|
2016-07-20 |
2018-01-30 |
南京亿华药业有限公司 |
一种依鲁替尼及其关键中间体的制备新方法
|
RU2019104758A
(ru)
|
2016-07-21 |
2020-08-21 |
Байоджен Ма Инк. |
Сукцинатные формы и композиции ингибиторов тирозинкиназы брутона
|
CN116478166A
(zh)
|
2016-08-16 |
2023-07-25 |
百济神州(苏州)生物科技有限公司 |
一种化合物的晶型、其制备和用途
|
JP6737952B2
(ja)
*
|
2016-08-17 |
2020-08-12 |
深▲セン▼市塔吉瑞生物医▲薬▼有限公司Shenzhen TargetRx,Inc. |
チロシンキナーゼ活性を阻害するための縮合二環式化合物
|
US11701357B2
(en)
|
2016-08-19 |
2023-07-18 |
Beigene Switzerland Gmbh |
Treatment of B cell cancers using a combination comprising Btk inhibitors
|
KR20190058550A
(ko)
|
2016-09-19 |
2019-05-29 |
메이 파마, 아이엔씨. |
병용 요법
|
JP2019532959A
(ja)
*
|
2016-10-06 |
2019-11-14 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Btk阻害剤を調製するための方法および中間体
|
TWI825663B
(zh)
|
2016-10-14 |
2023-12-11 |
美商林伯士拉克許米公司 |
Tyk2抑制劑及其用途
|
WO2018074387A1
(ja)
|
2016-10-17 |
2018-04-26 |
第一三共株式会社 |
Mdm2阻害剤とdnaメチルトランスフェラーゼ阻害剤との併用治療法
|
EP3528816A4
(en)
|
2016-10-21 |
2020-04-08 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
MX2019005029A
(es)
|
2016-11-03 |
2019-10-24 |
Juno Therapeutics Inc |
Terapia de combinación de una terapia de células t y un inhibidor de tirosina cinasa de bruton (btk).
|
EP3538091A4
(en)
|
2016-11-08 |
2020-06-10 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
|
CA3043376A1
(en)
*
|
2016-11-15 |
2018-05-24 |
Hangzhou Hertz Pharmaceutical Co., Ltd. |
L-h-pyrazolo[3,4-d]pyrimidinyl derivatives and pharmaceutical compositions thereof useful as selective bruton's tyrosine kinase inhibitor
|
CN108101905A
(zh)
*
|
2016-11-24 |
2018-06-01 |
中国科学院上海药物研究所 |
嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
US10183024B2
(en)
|
2016-12-02 |
2019-01-22 |
Apotex Inc. |
Crystalline forms of ibrutinib
|
EP3548046A2
(en)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics, Inc. |
Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
|
WO2018106636A1
(en)
|
2016-12-05 |
2018-06-14 |
Raze Therapeutics, Inc. |
Shmt inhibitors and uses thereof
|
KR102559851B1
(ko)
|
2016-12-21 |
2023-07-25 |
아세르타 파마. 비.브이. |
브루톤 티로신 키나제의 이미다조피라진 저해제
|
WO2018115203A1
(en)
|
2016-12-23 |
2018-06-28 |
Bicyclerd Limited |
Peptide derivatives having novel linkage structures
|
WO2018127699A1
(en)
|
2017-01-06 |
2018-07-12 |
Bicyclerd Limited |
Compounds for treating cancer
|
TWI774726B
(zh)
|
2017-01-25 |
2022-08-21 |
英屬開曼群島商百濟神州有限公司 |
(S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途
|
WO2018151849A1
(en)
|
2017-02-17 |
2018-08-23 |
Privo Technologies, Inc. |
Particle-based multi-layer therapeutic delivery device and method
|
TWI754011B
(zh)
|
2017-02-24 |
2022-02-01 |
美商基利科學股份有限公司 |
布魯頓氏酪胺酸激酶之抑制劑
|
EP3585789A1
(en)
|
2017-02-24 |
2020-01-01 |
Gilead Sciences, Inc. |
Inhibitors of bruton's tyrosine kinase
|
CA3055209A1
(en)
|
2017-03-08 |
2018-09-13 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors, uses, and methods for production thereof
|
CN108570036A
(zh)
*
|
2017-03-09 |
2018-09-25 |
北京赛林泰医药技术有限公司 |
一种btk抑制剂的多晶型物及其制备方法
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
AU2018236233A1
(en)
*
|
2017-03-14 |
2019-09-19 |
Dana-Farber Cancer Institute, Inc. |
Small molecule sensitization of BAX activation for induction of cell death
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
CN110494433B
(zh)
|
2017-03-22 |
2023-03-17 |
廖细斌 |
布鲁顿酪氨酸激酶抑制剂
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
WO2018191815A1
(en)
|
2017-04-20 |
2018-10-25 |
Apotex Inc. |
Processes for the preparation of acalabrutinib and intermediates thereof
|
CN107043366B
(zh)
*
|
2017-04-25 |
2020-05-26 |
中国药科大学 |
4-氨基嘧啶类化合物、其制备方法及医药用途
|
US10912750B2
(en)
|
2017-04-26 |
2021-02-09 |
Navitor Pharmaceuticals, Inc. |
Modulators of Sestrin-GATOR2 interaction and uses thereof
|
EP3615550A1
(en)
|
2017-04-27 |
2020-03-04 |
BicycleTx Limited |
Bicyclic peptide ligands and uses thereof
|
US10478403B1
(en)
|
2017-05-03 |
2019-11-19 |
Privo Technologies, Inc. |
Intraoperative topically-applied non-implantable rapid release patch
|
EP3631468A1
(en)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
JP2020522489A
(ja)
|
2017-06-02 |
2020-07-30 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いる処置のための製造物品および方法
|
CN109111446B
(zh)
|
2017-06-22 |
2021-11-30 |
上海度德医药科技有限公司 |
一种具有药物活性的杂芳基化合物
|
US10899798B2
(en)
|
2017-06-26 |
2021-01-26 |
Bicyclerd Limited |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
KR20200020902A
(ko)
|
2017-06-26 |
2020-02-26 |
베이진 엘티디 |
간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
|
WO2019006427A1
(en)
|
2017-06-29 |
2019-01-03 |
Juno Therapeutics, Inc. |
WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
|
KR102384924B1
(ko)
*
|
2017-07-12 |
2022-04-08 |
주식회사 대웅제약 |
신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
|
WO2019013562A1
(ko)
|
2017-07-12 |
2019-01-17 |
주식회사 대웅제약 |
신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
|
US11046698B2
(en)
|
2017-07-28 |
2021-06-29 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
CN110997677A
(zh)
|
2017-08-12 |
2020-04-10 |
百济神州有限公司 |
具有改进的双重选择性的Btk抑制剂
|
WO2019034868A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
|
EP3668887A1
(en)
|
2017-08-14 |
2020-06-24 |
Bicyclerd Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
WO2019046491A1
(en)
|
2017-08-29 |
2019-03-07 |
Ariya Therapeutics, Inc. |
LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
|
WO2019046832A1
(en)
|
2017-09-01 |
2019-03-07 |
Juno Therapeutics, Inc. |
GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
IL295603B2
(en)
|
2017-09-22 |
2024-03-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
EA037031B1
(ru)
*
|
2017-10-06 |
2021-01-28 |
Асерта Фарма Б.В. |
Имидазопиразиновые ингибиторы тирозинкиназы брутона
|
KR102613433B1
(ko)
*
|
2017-10-11 |
2023-12-13 |
주식회사 대웅제약 |
신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
|
TW201922256A
(zh)
|
2017-10-27 |
2019-06-16 |
中國大陸商浙江導明醫藥科技有限公司 |
治療淋巴樣惡性疾病之方法
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
CZ2017787A3
(cs)
|
2017-12-08 |
2019-06-19 |
Zentiva, K.S. |
Farmaceutické kompozice obsahující ibrutinib
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
WO2019126378A1
(en)
|
2017-12-19 |
2019-06-27 |
Ariya Therapeutics, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
WO2019127008A1
(zh)
*
|
2017-12-26 |
2019-07-04 |
清华大学 |
一种靶向降解btk的化合物及其应用
|
MX2020006812A
(es)
|
2017-12-26 |
2020-11-06 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
CN108220261B
(zh)
*
|
2017-12-29 |
2021-05-14 |
安徽联创生物医药股份有限公司 |
酮还原酶、核酸、重组表达载体、重组表达菌株及应用
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
US11576917B2
(en)
|
2018-01-20 |
2023-02-14 |
Natco Pharma Limited |
Pharmaceutical compositions comprising Ibrutinib
|
CN111867581B
(zh)
|
2018-01-29 |
2023-12-26 |
默克专利股份有限公司 |
Gcn2抑制剂及其用途
|
SG11202006701TA
(en)
|
2018-01-29 |
2020-08-28 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
IL301120A
(en)
|
2018-02-27 |
2023-05-01 |
Artax Biopharma Inc |
A history of novel chromium as TCR–NCK interaction inhibitors
|
AU2019247498A1
(en)
|
2018-04-05 |
2020-11-26 |
Sumitomo Pharma Oncology, Inc. |
AXL kinase inhibitors and use of the same
|
CN117959303A
(zh)
|
2018-04-13 |
2024-05-03 |
住友制药肿瘤公司 |
用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
|
ES2969982T3
(es)
|
2018-04-24 |
2024-05-23 |
Vertex Pharma |
Compuestos de pteridinona y usos de los mismos
|
TWI813673B
(zh)
|
2018-04-24 |
2023-09-01 |
德商馬克專利公司 |
抗增生化合物及其用途
|
EP3789040A4
(en)
|
2018-04-27 |
2022-03-09 |
ONO Pharmaceutical Co., Ltd. |
PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
|
KR102106821B1
(ko)
|
2018-04-27 |
2020-05-06 |
재단법인대구경북과학기술원 |
이브루티닙을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
|
WO2019213184A1
(en)
|
2018-05-03 |
2019-11-07 |
Juno Therapeutics, Inc. |
Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
|
TW202014412A
(zh)
|
2018-05-04 |
2020-04-16 |
美商普托拉製藥有限公司 |
賽度替尼(cerdulatinib)之固體型式
|
EP3575300A1
(en)
|
2018-05-31 |
2019-12-04 |
Apotex Inc. |
Novel crystalline forms of ibrutinib
|
IL259810A
(en)
|
2018-06-04 |
2018-07-31 |
Yeda Res & Dev |
Mitogen-activated protein kinase kinase 7 inhibitors
|
RU2711106C2
(ru)
*
|
2018-06-06 |
2020-01-15 |
Общество с ограниченной ответственностью "АКСЕЛЬФАРМ" |
Кристаллическая μ-модификация 1-[(3R)-3-[4-амино-3-(4-фенокси-фенил)-1Н-пиразоло[3,4-d]пиримидин-1-ил]-1-пиперидил]-2-пропенил-1-она, способ её получения и фармацевтическая композиция на её основе
|
US10980784B2
(en)
|
2018-06-15 |
2021-04-20 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
KR20210021348A
(ko)
|
2018-06-15 |
2021-02-25 |
얀센 파마슈티카 엔.브이. |
이브루티닙을 포함하는 제형/조성물
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
WO2020023910A1
(en)
|
2018-07-26 |
2020-01-30 |
Tolero Pharmaceuticals, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
CN113194928A
(zh)
|
2018-07-31 |
2021-07-30 |
罗索肿瘤学公司 |
(s)-5-氨基-3-(4-((5-氟-2-甲氧基苯甲酰胺基)甲基)苯基)-1-(1,1,1-三氟丙-2-基)-1h-吡唑-4-甲酰胺的喷雾干燥的分散体和制剂
|
WO2020045941A1
(ko)
|
2018-08-27 |
2020-03-05 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
CA3111126A1
(en)
*
|
2018-08-31 |
2020-03-05 |
Stichting Katholieke Universiteit |
Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
|
WO2020051424A1
(en)
|
2018-09-07 |
2020-03-12 |
Pic Therapeutics |
Eif4e inhibitors and uses thereof
|
CN110964016B
(zh)
*
|
2018-09-29 |
2021-05-28 |
南京药捷安康生物科技有限公司 |
氨基降茨烷衍生物及其制备方法与应用
|
JP2022502515A
(ja)
|
2018-10-15 |
2022-01-11 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用
|
CN112955459A
(zh)
|
2018-10-23 |
2021-06-11 |
拜斯科技术开发有限公司 |
双环肽配体和其用途
|
CA3117336A1
(en)
|
2018-10-24 |
2020-04-30 |
Navitor Pharmaceuticals, Inc. |
Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1
|
CN111170986A
(zh)
|
2018-11-13 |
2020-05-19 |
北京睿熙生物科技有限公司 |
布鲁顿酪氨酸激酶的抑制剂
|
CN109293630A
(zh)
*
|
2018-11-15 |
2019-02-01 |
山东大学 |
含取代吡唑类化合物及其制备方法与应用
|
CN109369654A
(zh)
*
|
2018-11-20 |
2019-02-22 |
山东大学 |
1,3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用
|
BR112021010120A2
(pt)
|
2018-11-30 |
2021-08-31 |
Juno Therapeutics, Inc. |
Métodos para dosagem e tratamento de malignidades celulares em terapia celular adotiva
|
JP2022513685A
(ja)
|
2018-11-30 |
2022-02-09 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いた処置のための方法
|
US11053241B2
(en)
|
2018-11-30 |
2021-07-06 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
EP3886904A4
(en)
|
2018-11-30 |
2022-07-13 |
Kymera Therapeutics, Inc. |
IRAQ-TYPE KINASE DEGRADING AGENTS AND THEIR USES
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN DEGRADATION
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
EP3669867A1
(en)
|
2018-12-21 |
2020-06-24 |
Synthon B.V. |
Pharmaceutical composition comprising ibrutinib
|
US10688050B1
(en)
|
2018-12-21 |
2020-06-23 |
Synthon B.V. |
Pharmaceutical composition comprising ibrutinib
|
AU2019407426A1
(en)
|
2018-12-21 |
2021-07-22 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
AU2020206884A1
(en)
|
2019-01-09 |
2021-08-05 |
Beth Israel Deaconess Medical Center, Inc. |
Modulators of Pin1 activity and uses thereof
|
CN111454268B
(zh)
*
|
2019-01-18 |
2023-09-08 |
明慧医药(上海)有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
AU2020212001A1
(en)
|
2019-01-23 |
2021-07-22 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
CN113412262A
(zh)
|
2019-02-12 |
2021-09-17 |
大日本住友制药肿瘤公司 |
包含杂环蛋白激酶抑制剂的制剂
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
WO2020170270A1
(en)
*
|
2019-02-19 |
2020-08-27 |
Msn Laboratories Private Limited, R&D Center |
Novel crystalline polymorphs of 1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and process for preparation thereof
|
MX2021009863A
(es)
|
2019-03-21 |
2021-11-12 |
Onxeo |
Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
CA3135802A1
(en)
|
2019-04-05 |
2020-10-08 |
Kymera Therapeutics, Inc. |
Stat degraders and uses thereof
|
WO2020234379A1
(en)
|
2019-05-21 |
2020-11-26 |
Janssen Pharmaceutica Nv |
Processes and intermediates for preparing a btk inhibitor
|
US20220204516A1
(en)
|
2019-05-21 |
2022-06-30 |
Janssen Pharmaceutica Nv |
Processes and intermediates for preparing a btk inhibitor
|
CA3137880A1
(en)
*
|
2019-05-28 |
2020-12-03 |
Rodrigo CEBALLOS LENTINI |
Systems and methods for processing images to prepare slides for processed images for digital pathology
|
JP2022534425A
(ja)
|
2019-05-31 |
2022-07-29 |
イケナ オンコロジー, インコーポレイテッド |
Tead阻害剤およびその使用
|
TW202110485A
(zh)
|
2019-07-30 |
2021-03-16 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
WO2021038540A1
(en)
|
2019-08-31 |
2021-03-04 |
Sun Pharma Advanced Research Company Limited |
Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
|
JP2022548594A
(ja)
|
2019-09-11 |
2022-11-21 |
ビンシア・バイオサイエンシーズ・インコーポレイテッド |
Usp30阻害剤及びその使用
|
CN114945366A
(zh)
|
2019-09-13 |
2022-08-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
CA3156436A1
(en)
|
2019-11-01 |
2021-05-06 |
Steven LEVENTER |
Methods of treatment using an mtorc1 modulator
|
EP4054579A1
(en)
|
2019-11-08 |
2022-09-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
EP4069223A4
(en)
|
2019-12-05 |
2023-12-20 |
Janssen Pharmaceutica NV |
RAPAMYCIN ANALOGS AND THEIR USES
|
KR20220132527A
(ko)
|
2019-12-06 |
2022-09-30 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B 세포 악성 종양을 치료하기 위한 세포 요법과 연관된 독성 및 반응과 관련된 방법
|
US11779578B2
(en)
|
2019-12-17 |
2023-10-10 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
WO2021133920A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
IL294560A
(en)
|
2020-01-20 |
2022-09-01 |
Genzyme Corp |
Medicinal tyrosine kinase inhibitors for relapsing multiple sclerosis
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
EP4100017A4
(en)
|
2020-02-05 |
2024-04-10 |
Puretech Lyt Inc |
LIPID PRODRUGS OF NEUROSTEROIDS
|
CN113336760B
(zh)
*
|
2020-02-18 |
2022-11-04 |
深圳市塔吉瑞生物医药有限公司 |
取代的酰胺衍生物及其组合物及用途
|
WO2021172922A1
(ko)
|
2020-02-26 |
2021-09-02 |
주식회사 대웅제약 |
헤테로사이클릭아민 유도체의 제조 방법
|
JP2023515888A
(ja)
|
2020-03-03 |
2023-04-14 |
ピク セラピューティクス, インコーポレイテッド |
eIF4E阻害剤及びその使用
|
JP2023518423A
(ja)
|
2020-03-19 |
2023-05-01 |
カイメラ セラピューティクス, インコーポレイテッド |
Mdm2分解剤およびそれらの使用
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
CN114057724A
(zh)
*
|
2020-07-29 |
2022-02-18 |
鲁南制药集团股份有限公司 |
一种btk抑制剂
|
MX2023001588A
(es)
|
2020-08-17 |
2023-05-03 |
Bicycletx Ltd |
Conjugados biciclo específicos para nectina-4 y usos de estos.
|
WO2022043251A1
(en)
|
2020-08-28 |
2022-03-03 |
Synthon B.V. |
Pharmaceutical composition comprising ibrutinib
|
EP4203942A1
(en)
*
|
2020-08-28 |
2023-07-05 |
Emory University |
Methods of managing cocaine or other drug addictions
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
CA3200814A1
(en)
|
2020-12-02 |
2022-06-09 |
Alfredo C. Castro |
Tead inhibitors and uses thereof
|
CN112574216B
(zh)
*
|
2020-12-16 |
2022-03-08 |
天津济坤医药科技有限公司 |
一种化合物及其制备方法以及其在制备治疗抗癌药物中的应用
|
EP4281454A1
(en)
|
2021-01-21 |
2023-11-29 |
Synthon B.V. |
Process for making ibrutinib
|
WO2022167457A1
(en)
|
2021-02-02 |
2022-08-11 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
AU2022215844A1
(en)
|
2021-02-02 |
2023-09-14 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
US11773103B2
(en)
|
2021-02-15 |
2023-10-03 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
WO2022187856A1
(en)
|
2021-03-05 |
2022-09-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
WO2022221866A1
(en)
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
AU2022286943A1
(en)
*
|
2021-06-01 |
2023-12-07 |
Privo Technologies, Inc. |
Enhanced two-stage microparticle-based localized therapeutic delivery system
|
WO2022260667A1
(en)
|
2021-06-10 |
2022-12-15 |
Hikma Pharmaceuticals Usa Inc. |
Oral dosage forms of ibrutinib
|
US11433072B1
(en)
|
2021-06-10 |
2022-09-06 |
Hikma Pharmaceuticals USA, Inc. |
Oral dosage forms of ibrutinib
|
CN113583001A
(zh)
*
|
2021-07-13 |
2021-11-02 |
江苏君若药业有限公司 |
依鲁替尼的制备
|
WO2023014817A1
(en)
|
2021-08-03 |
2023-02-09 |
Syros Pharmaceuticals, Inc. |
Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
|
CN115702898B
(zh)
*
|
2021-08-04 |
2024-02-09 |
成都倍特药业股份有限公司 |
一种btk抑制剂固体制剂及其制备方法
|
CN118019739A
(zh)
|
2021-08-25 |
2024-05-10 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
EIF4E inhibitors and their uses
|
CN113845521B
(zh)
*
|
2021-08-31 |
2024-06-18 |
中原工学院 |
水相中光催化一锅法合成咪唑并含氮杂环肼类衍生物的方法
|
WO2023071973A1
(en)
*
|
2021-10-26 |
2023-05-04 |
Shenzhen Targetrx, Inc. |
Fused bicyclic compound for inhibiting activity of tyrosine kinase
|
WO2023104808A1
(en)
|
2021-12-10 |
2023-06-15 |
Synthon B.V. |
Pharmaceutical composition comprising ibrutinib
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
CN114605418B
(zh)
*
|
2022-03-15 |
2023-09-05 |
广东医科大学附属医院 |
一类具有抗肿瘤活性的依鲁替尼丙烯酰胺类衍生物及其合成方法与应用
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
TW202404581A
(zh)
|
2022-05-25 |
2024-02-01 |
美商醫肯納腫瘤學公司 |
Mek抑制劑及其用途
|
US11814439B1
(en)
|
2022-06-01 |
2023-11-14 |
Tg Therapeutics, Inc. |
Anti-CD20 antibody compositions
|
US11965032B1
(en)
|
2022-06-01 |
2024-04-23 |
Tg Therapeutics, Inc. |
Anti-CD20 antibody compositions
|
US11884740B1
(en)
|
2022-06-01 |
2024-01-30 |
Tg Therapeutics, Inc. |
Anti-CD20 antibody compositions
|
US11807689B1
(en)
|
2022-06-01 |
2023-11-07 |
Tg Therapeutics, Inc. |
Anti-CD20 antibody compositions
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
WO2023242384A1
(en)
|
2022-06-17 |
2023-12-21 |
Krka, D.D., Novo Mesto |
Crystalline form of ibrutinib
|
WO2023249980A1
(en)
*
|
2022-06-22 |
2023-12-28 |
Genzyme Corporation |
Methods of making modified btk inhibitors
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
CN115417827B
(zh)
*
|
2022-09-30 |
2023-05-26 |
中国药科大学 |
6-氨基-1,3,5-三嗪类化合物及其合成方法和应用
|
WO2024097653A1
(en)
|
2022-10-31 |
2024-05-10 |
Sumitomo Pharma America, Inc. |
Pim1 inhibitor for treating myeloproliferative neoplasms
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|